387 related articles for article (PubMed ID: 31770016)
21. Ethanol extract of propolis regulates type 2 diabetes in mice via metabolism and gut microbiota.
Guan R; Ma N; Liu G; Wu Q; Su S; Wang J; Geng Y
J Ethnopharmacol; 2023 Jun; 310():116385. PubMed ID: 36931413
[TBL] [Abstract][Full Text] [Related]
22. Effect of pioglitazone and acarbose on endothelial inflammation biomarkers during oral glucose tolerance test in diabetic patients treated with sulphonylureas and metformin.
Derosa G; Mereu R; D'Angelo A; Salvadeo SA; Ferrari I; Fogari E; Gravina A; Palumbo I; Maffioli P; Randazzo S; Cicero AF
J Clin Pharm Ther; 2010 Oct; 35(5):565-79. PubMed ID: 20831680
[TBL] [Abstract][Full Text] [Related]
23. The anti-diabetic activities, gut microbiota composition, the anti-inflammatory effects of Scutellaria-coptis herb couple against insulin resistance-model of diabetes involving the toll-like receptor 4 signaling pathway.
Zhang CH; Sheng JQ; Sarsaiya S; Shu FX; Liu TT; Tu XY; Ma GQ; Xu GL; Zheng HX; Zhou LF
J Ethnopharmacol; 2019 Jun; 237():202-214. PubMed ID: 30807814
[TBL] [Abstract][Full Text] [Related]
24. DLBS3233, a combined bioactive fraction of Cinnamomum burmanii and Lagerstroemia speciosa, in type-2 diabetes mellitus patients inadequately controlled by metformin and other oral antidiabetic agents.
Tjokroprawiro A; Murtiwi S; Tjandrawinata RR
J Complement Integr Med; 2016 Dec; 13(4):413-420. PubMed ID: 27451997
[TBL] [Abstract][Full Text] [Related]
25. A specific gut microbiota and metabolomic profiles shifts related to antidiabetic action: The similar and complementary antidiabetic properties of type 3 resistant starch from Canna edulis and metformin.
Zhang C; Ma S; Wu J; Luo L; Qiao S; Li R; Xu W; Wang N; Zhao B; Wang X; Zhang Y; Wang X
Pharmacol Res; 2020 Sep; 159():104985. PubMed ID: 32504839
[TBL] [Abstract][Full Text] [Related]
26. Metformin: old friend, new ways of action-implication of the gut microbiome?
Rodriguez J; Hiel S; Delzenne NM
Curr Opin Clin Nutr Metab Care; 2018 Jul; 21(4):294-301. PubMed ID: 29634493
[TBL] [Abstract][Full Text] [Related]
27. Gut microbiome encoded purine and amino acid pathways present prospective biomarkers for predicting metformin therapy efficacy in newly diagnosed T2D patients.
Elbere I; Orlovskis Z; Ansone L; Silamikelis I; Jagare L; Birzniece L; Megnis K; Leskovskis K; Vaska A; Turks M; Klavins K; Pirags V; Briviba M; Klovins J
Gut Microbes; 2024; 16(1):2361491. PubMed ID: 38868903
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of initial combination therapy with gemigliptin and metformin compared with monotherapy with either drug in patients with type 2 diabetes: A double-blind randomized controlled trial (INICOM study).
Lim S; Han KA; Yu J; Chamnan P; Kim ES; Yoon KH; Kwon S; Moon MK; Lee KW; Kim DJ; Kim M; Wongtanate M; Kim EY; Kim SH; Lee MK;
Diabetes Obes Metab; 2017 Jan; 19(1):87-97. PubMed ID: 27619558
[TBL] [Abstract][Full Text] [Related]
29. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial.
Fonseca V; Rosenstock J; Patwardhan R; Salzman A
JAMA; 2000 Apr; 283(13):1695-702. PubMed ID: 10755495
[TBL] [Abstract][Full Text] [Related]
30. Effects of 12-week treatment with dapagliflozin and gliclazide on faecal microbiome: Results of a double-blind randomized trial in patients with type 2 diabetes.
van Bommel EJM; Herrema H; Davids M; Kramer MHH; Nieuwdorp M; van Raalte DH
Diabetes Metab; 2020 Apr; 46(2):164-168. PubMed ID: 31816432
[TBL] [Abstract][Full Text] [Related]
31. Liraglutide and sitagliptin have no effect on intestinal microbiota composition: A 12-week randomized placebo-controlled trial in adults with type 2 diabetes.
Smits MM; Fluitman KS; Herrema H; Davids M; Kramer MHH; Groen AK; Belzer C; de Vos WM; Cahen DL; Nieuwdorp M; van Raalte DH
Diabetes Metab; 2021 Sep; 47(5):101223. PubMed ID: 33429063
[TBL] [Abstract][Full Text] [Related]
32. Prebiotic Mannan-Oligosaccharides Augment the Hypoglycemic Effects of Metformin in Correlation with Modulating Gut Microbiota.
Zheng J; Li H; Zhang X; Jiang M; Luo C; Lu Z; Xu Z; Shi J
J Agric Food Chem; 2018 Jun; 66(23):5821-5831. PubMed ID: 29701959
[TBL] [Abstract][Full Text] [Related]
33. Trans-ethnic gut microbiota signatures of type 2 diabetes in Denmark and India.
Alvarez-Silva C; Kashani A; Hansen TH; Pinna NK; Anjana RM; Dutta A; Saxena S; Støy J; Kampmann U; Nielsen T; Jørgensen T; Gnanaprakash V; Gnanavadivel R; Sukumaran A; Rani CSS; Færch K; Radha V; Balasubramanyam M; Nair GB; Das B; Vestergaard H; Hansen T; Mande SS; Mohan V; Arumugam M; Pedersen O
Genome Med; 2021 Mar; 13(1):37. PubMed ID: 33658058
[TBL] [Abstract][Full Text] [Related]
34. The combination metformin/glyburide exerts its hypoglycemic effect mainly by increasing insulin secretion: a controlled, randomized, double-blind, crossover study.
Gulias-Herrero A; Aguilar-Salinas CA; Gómez-Pérez FJ; Rull JA
Diabetes Nutr Metab; 2003; 16(5-6):268-76. PubMed ID: 15000437
[TBL] [Abstract][Full Text] [Related]
35. Corni Fructus as a Natural Resource Can Treat Type 2 Diabetes by Regulating Gut Microbiota.
Niu D; An S; Chen X; Bi H; Zhang Q; Wang T; Han B; Zhang H; Kang J
Am J Chin Med; 2020; 48(6):1385-1407. PubMed ID: 32907359
[TBL] [Abstract][Full Text] [Related]
36. Effects of metformin, acarbose, and sitagliptin monotherapy on gut microbiota in Zucker diabetic fatty rats.
Zhang M; Feng R; Yang M; Qian C; Wang Z; Liu W; Ma J
BMJ Open Diabetes Res Care; 2019; 7(1):e000717. PubMed ID: 31641523
[TBL] [Abstract][Full Text] [Related]
37. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study.
Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Gravina A; Mereu R; Palumbo I; D'Angelo A; Cicero AF
Metabolism; 2009 Aug; 58(8):1059-66. PubMed ID: 19394976
[TBL] [Abstract][Full Text] [Related]
38. Metformin in women with type 2 diabetes in pregnancy (MiTy): a multicentre, international, randomised, placebo-controlled trial.
Feig DS; Donovan LE; Zinman B; Sanchez JJ; Asztalos E; Ryan EA; Fantus IG; Hutton E; Armson AB; Lipscombe LL; Simmons D; Barrett JFR; Karanicolas PJ; Tobin S; McIntyre HD; Tian SY; Tomlinson G; Murphy KE;
Lancet Diabetes Endocrinol; 2020 Oct; 8(10):834-844. PubMed ID: 32946820
[TBL] [Abstract][Full Text] [Related]
39. Comparison of vildagliptin and glimepiride: effects on glycaemic control, fat tolerance and inflammatory markers in people with type 2 diabetes.
Derosa G; Bonaventura A; Bianchi L; Romano D; Fogari E; D'Angelo A; Maffioli P
Diabet Med; 2014 Dec; 31(12):1515-23. PubMed ID: 24824633
[TBL] [Abstract][Full Text] [Related]
40. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
Robbins DC; Beisswenger PJ; Ceriello A; Goldberg RB; Moses RG; Pagkalos EM; Milicevic Z; Jones CA; Sarwat S; Tan MH
Clin Ther; 2007 Nov; 29(11):2349-64. PubMed ID: 18158076
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
